Thrombotic Thrombocytopenic Purpura

Thrombotic thrombocytopenic purpura (TTP) is a blood disorder that occurs when there is an abnormally low number of platelets in the body, leading to a increased risk of clotting and bleeding. It is caused by a deficiency of the enzyme ADAMTS-13, which is essential for breaking down large molecules involved in clot formation. TTP can be life-threatening if left untreated, and is most commonly treated with plasma exchange or IVIG (intravenous immunoglobulin). In recent years, new therapies such as rituximab, eculizumab, and eltrombopag have been developed to help improve the outcomes of TTP patients. Therefore, TTP is a serious condition that requires prompt medical attention, and proper treatment can greatly reduce the chances of a fatal outcome.